化痰息风通络汤联合依达拉奉右莰醇治疗脑梗死临床疗效分析

Clinical Efficacy Analysis of Huatan Xifeng Tongluo Decoction Combined with Edaravondextrocamphenol Treating Acute Cerebral Infarction

目的:探讨化痰息风通络汤联合依达拉奉右莰醇治疗急性脑梗死(ACI)的疗效。方法:选取2021年1月—2023年3月无锡市中医医院和宿迁市中医院收治的205例ACI患者,按照随机数表法分为对照组(102例)和试验组(103例)。试验组和对照组患者因自然失访分别脱落2例和3例,两组纳入最终研究的分别为101例和99例。对照组给予依达拉奉右莰醇注射用浓溶液,试验组在对照组基础上加用化痰息风通络汤。两组患者疗程均为10 d。比较两组患者神经功能、自理功能、临床疗效、血液流变学指标、肝肾功能、神经元特异性烯醇化酶(NSE)及药物安全性。结果:治疗后,试验组美国国立卫生研究院卒中量表(NIHSS)、改良Rankin量表(mRS)评分、血浆黏度、全血高切黏度、全血低切黏度、NSE评分低于治疗前(P<0.05),且低于对照组(P<0.05),Barthel指数(BI)评分高于治疗前(P<0.05)且高于对照组(P<0.05);试验组总有效率高于对照组(P<0.05);两组安全性结果比较差异无统计学意义(P>0.05)。结论:化痰息风通络汤联合依达拉奉右莰醇治疗ACI可增强治疗效果,改善患者神经功能,增强自理能力,改善血液流变学及脑神经损伤,且安全性良好。

Objective:To investigate the efficacy of Huatan Xifeng Tongluo Decoction combined with Edaravondextrocamphenol in treating acute cerebral infarction(ACI).Methods:A total of 205 patients with ACI treated at Wuxi Hospital of Traditional Chinese Medicine and Suqian Hospital of Traditional Chinese Medicine from January 2021 to March 2023 were randomly divided into a control group(102 patients)and a test group(103 patients)using a random number table method.After natural loss to follow-up,2 patients from the test group and 3 patients from the control group were excluded,resulting in 101 patients in the control group and 99 patients in the test group for final analysis.The control group received Edaravondextrocamphenol injection,while the test group received the same plus Huatan Xifeng Tongluo Decoction.Both groups underwent treatment for 10 days.Comparisons were made between the two groups regarding neurological function,self-care ability,clinical efficacy,hematorheological indices,liver and kidney function,neuron-specific enolase(NSE),and drug safety.Results:After treatment,the test group showed lower scores on the National Institutes of Health Stroke Scale(NIHSS),modified Rankin Scale(mRS),plasma viscosity,whole blood high shear viscosity,whole blood low shear viscosity,and NSE compared to pre-treatment levels(P<0.05)and also lower than the control group(P<0.05).The Barthel Index(BI)score was higher in the test group compared to pre-treatment levels(P<0.05)and also higher than in the control group(P<0.05).The overall effective rate in the test group was higher than that in the control group(P<0.05).There were no statistically significant differences in safety outcomes between the two groups(P>0.05).Conclusion:Huatan Xifeng Tongluo Decoction combined with Edaravondextrocamphenol can enhance treatment efficacy for ACI,improve neurological function,increase self-care ability,improve hematorheological parameters,and reduce neuronal injury,with good safety.